Dicot

"It is very pleasing that we are once again seeing strong support from our major shareholders, board and management. This confidence means a lot and it feels extra valuable to be able to announce this even before the subscription period has begun", says Elin Trampe, CEO.

One warrant of series TO 6 entitles to subscribe for two new shares at SEK 0.19 per share. To prevent the warrants from expiring worthless, the holder must actively subscribe for shares by March 31, 2025, or alternatively sell the warrants by March 27, 2025.

If all warrants are exercised for the subscription of new shares, Dicot Pharma will receive approximately SEK 45.7 million before issuance costs.

The terms and conditions regarding the warrants are available on Dicot Pharma's website www.dicotpharma.com.